Company ProfilePremium

Alembic Limited

Company Profile Analysis

Tickers: ALEMBICLTD.NS, 506235.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alembic Limited - Company showcase

Year Founded & Workforce

1907

256 Employees

Alembic Limited logo

Alembic Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alembic Limited Overview

MetricFY2024FY2025FY2026
Employees (number)—285256

FY2024 headcount not publicly disclosed in sources reviewed; FY2026 figure from Morningstar (Zonebourse shows 261).

Alembic Limited is the 1907-founded parent of India's Alembic Group and one of the country's oldest pharmaceutical enterprises. Following the 2010 demerger of its formulations business into Alembic Pharmaceuticals Limited (APL), it has evolved into a hybrid holding-and-operating company with three value pillars. First, an equity-accounted ~28.5% stake in APL — a ₹7,000+ crore-revenue US-generics and India-branded pharma major — which generated ₹191 crore of associate profit in FY2026, roughly 60% of Alembic Limited's consolidated net profit. Second, a Vadodara-centric real estate development and leasing business built on legacy industrial land ("Alembic City"), which contributed 81% of FY2026 operating revenue. Third, a small fermentation- and chemistry-based API manufacturing unit plus captive co-generation/wind power assets. A ~19% stake in phosgene-chemistry specialist Paushak Limited rounds out the portfolio. The stock trades at a pronounced holding-company discount to the market value of its listed stakes.


Company's own description

The company's exchange-filed profile and its website describe Alembic Limited as engaged in pharmaceuticals (Active Pharmaceutical Ingredients), real estate, and power assets (co-generation plants of 11 MW in aggregate and wind power). Its two reportable segments under Ind AS 108 are Active Pharmaceutical Ingredients (API) and Real Estate. Third-party profiles (Morningstar, Simply Wall St) characterise the API segment as manufacturing and marketing fermentation- and chemistry-based APIs, and the real estate segment as constructing residential and commercial projects, providing project management and marketing consultancy, and leasing commercial properties.

Independent characterisation

Alembic Limited is best understood as a promoter-controlled holding company with an operating real-estate tail. Three economic engines drive its reported numbers:

  1. Associate income from APL (non-cash in P&L; cash via dividends). Under Ind AS 28, Alembic Limited books its share of APL's profit. In FY2026 this was INR 191.45 crore versus INR 125.93 crore of the company's own (pre-associate) net profit (ScanX summary of FY2026 audited consolidated results). The cash link is APL's dividend: standalone FY2026 dividend receipts were INR 62.95 crore, which almost exactly funded Alembic Limited's own INR 61.41 crore dividend payout (standalone FY2026 cash-flow statement, NSE filing).

  2. Real estate (operating cash engine). Revenue is recognised on a completion/transfer basis from residential projects in Alembic City West, Vadodara (townhouses, villas, mid-rise apartments) plus rental income from investment property (INR 299.59 crore carrying value at 31 March 2026) leased in part to group companies such as APL and Alembic City Limited.

  3. API (sub-scale manufacturing). FY2026 revenue INR 46.59 crore with standalone segment profit of INR 5.65 crore; a meaningful share of output appears to be sold to APL (standalone sales of goods/services to APL of INR 28.02 crore in H2 FY2026 alone, per the related-party disclosure — this figure also includes rentals and services, so the API-specific portion is not separately disclosed).

Revenue model mix (FY2026, consolidated)

Revenue typeFY2026 (INR Cr)Share of revenue (%)Nature
Real estate (sales of units, leasing, PMC/marketing consultancy)193.4080.6Project sale + recurring rental + fee
API products46.5919.4Product sales
Total revenue from operations239.99100.0—
Other income (dividends, interest, fair-value gains)72.97n/mTreasury/investment income
Share of associate profit (below PBT)191.45n/mEquity-accounted APL profit

Split between unit-sale revenue and lease rental within the real estate segment is not separately disclosed in the quarterly filings reviewed.

Value-chain position, customers and end-markets

BusinessValue-chain positionCustomer typesEnd-markets
Real estateLand owner-developer (legacy industrial land), lessorAffluent/upper-middle households in Vadodara; corporate tenants including group companiesVadodara (Gujarat) premium residential; commercial leasing
APIBulk-drug manufacturer (upstream of formulations)Formulators, including the associate APLDomestic and export pharma (geographic split not disclosed)
PowerCaptive co-generation (11 MW) and windInternal consumption; grid sale not disclosedCaptive
InvestmentsStrategic minority shareholder—US generics/India branded pharma (via APL); phosgene chemistry (via Paushak)

Strategy

Stated strategy

Alembic Limited does not publish investor presentations, earnings-call transcripts or medium-term guidance. Strategic intent must be inferred from filings and capital allocation:

  1. Monetise legacy Vadodara land through phased premium residential development. Successive RERA registrations (Townhouse24 2021, The Villas 2022, The Gardens 2023, Park Crescent 2024) show a cadence of roughly one new phase per year, sized at 10–72 units.

  2. Build recurring rental income. FY2026 investment property additions of INR 38.41 crore (standalone cash flow) indicate expansion of the leased commercial portfolio.

  3. Hold APL as the core long-term asset. No sell-down of the APL stake has been made; the dividend stream funds Alembic Limited's own payout.

  4. Maintain the API business as a group-linked operation, with capex in PPE of INR 38.25 crore in FY2026 (allocation between API and real estate not disclosed).

  5. Shareholder housekeeping. Investor-servicing initiatives in 2026: "Saksham Niveshak" 100-day campaign for unclaimed dividends (April 2026), special window for physical share dematerialisation, IEPF reminders.

Initiatives in the last 24 months

InitiativeDateDetailTarget
Park Crescent construction2024–202772 units; progress 45% by April 2026Possession July 2027
The Villas Phase 12022–2028Progress ~56% by April 2026Completion August 2028
Leadership transitionOct 2025 – Jan 2026Udit Amin MD; Malika Amin non-executive—
Investment property build-outFY2026INR 38.41 crore additions—
Labour Code complianceNov 2025INR 1.44 crore provision—
Investor-servicing campaignApr 2026Second 100-day "Saksham Niveshak" campaign—

ESG/sustainability commitments: captive 11 MW co-generation and wind power; CSR via Alembic CSR Foundation (approved INR 1.12 crore; INR 0.56 crore spent in H2 FY2026). No emissions targets disclosed.

Medium-term financial targets/guidance: none issued by Alembic Limited. The associate APL raised FY2027 revenue growth guidance to the mid-teens (from ~10–12%) and US generics guidance to mid-to-high teens after Q1 FY2027 (Multibagg summary of APL earnings call, Aug 2026) — this is the most relevant forward indicator for Alembic Limited's consolidated earnings.

Products & Services

Real Estate segment — project-by-project

ProjectLocationType & specificationTarget customerRERA / statusPricing (as listed)Source
SamsaraVadodaraResidential (maiden project)Upper-middle/affluent householdsCompleted 2014—Kotak company background
VedaVadodaraResidentialUpper-middle/affluent householdsLaunched FY2016—Kotak company background
Townhouse24Behind Bhailal Amin Hospital, Alembic City West, Gorwa24 townhouses, 3 blocks × 4 floors, 3 & 4 BHK, 2,659–3,343 sq ft; lift, power backup, yoga roomAffluent families seeking low-density livingRERA PR/GJ/VADODARA/VADODARA/Others/RAA08783/170721; possession date Dec 2025Listed INR 35–51 lakh (portal figure; appears inconsistent with unit size)Gharpe listing
The Villas Phase 1Alembic City West, VadodaraRERA describes 10 villas (portal states 22 luxury villas, 4 BHK, double-height terraces)Luxury segmentRERA PR/GJ/VADODARA/VADODARA/Others/RAA09703 approved 18 Jan 2022; completion due 31 Aug 2028; construction progress 55.92% (Apr 2026)From INR 80 lakh (portal)Aurum PropTech; Gharpe
The GardensAlembic City West, Vadodara14 residential flats, carpet area 3,496 sq mUpper-middleRERA PR/GJ/VADODARA/VADODARA/Others/RAA12047; status Completed; progress 89.38% (Jan 2026 filing)—Aurum PropTech
Park CrescentAlembic City West, Vadodara72 apartments, 2 towers × 10 floors, 3.5 & 4.5 BHK, 1,726–2,327 sq ftUpper-middle familiesRERA approved 23 Apr 2024; possession July 2027; progress 36.05% (Jan 2026) → 45.25% (Apr 2026)Listed INR 22–30 lakh (portal)Aurum PropTech; Gharpe
Commercial leasing portfolioAlembic Road / Alembic City, VadodaraInvestment property carrying value INR 299.59 crore (31 Mar 2026); additions of INR 38.41 crore in FY2026Corporate tenants incl. APL, Alembic City LtdOperatingLease rentals; not disclosedFY2026 standalone balance sheet & cash flow
Project management & marketing consultancyVadodaraFee-based services to group/related entitiesRelated partiesOperatingFee; not disclosedMorningstar/Simply Wall St profiles

Total project costs per RERA: The Villas Phase 1 INR 64.65 crore; The Gardens INR 36.61 crore. Aggregate unsold inventory, booking values and collections are not publicly disclosed by the company (no investor presentation is published).

API segment

OfferingDescriptionCustomerDetail available
Fermentation-based APIsBulk actives produced via fermentation — the company's historical core competencyFormulators incl. APLMolecule list not publicly disclosed in sources reviewed
Chemistry-based APIsSynthetic bulk activesFormulators—
Manufacturing sitesVadodara (Gujarat)—Kotak Securities

FY2026 API revenue was INR 46.59 crore (+44.6% YoY), the strongest growth in at least five years, with a standalone segment profit of INR 5.65 crore (12.1% margin). Q4 FY2026 API, however, swung to a segment loss of INR 1.17 crore (standalone FY2026 Q4 filing), indicating volatile utilisation.

Power assets

AssetSpecificationUse
Co-generation plants11 MW aggregateCaptive steam/power for Vadodara operations
Wind powerCapacity not disclosedCaptive/grid (not disclosed)

Strategic investments (portfolio "products" of the holding company)

HoldingShares heldStakeBusinessAccounting
Alembic Pharmaceuticals Ltd56,097,544~28.4–28.5%Integrated pharma: US generics (185 commercialised US products as of Q1 FY2027), India branded formulations, ex-US, APIEquity method (associate); cost INR 86.65 crore
Paushak Ltd4,702,472 (post 1:2 split and 3:1 bonus)~19.0–19.1%India's largest phosgene-based specialty chemicals maker (14,400 TPA phosgene plant)Fair value through OCI; INR 162.52 crore at 31 Mar 2026

Financial Narrative

Basis: consolidated unless stated. FY2021–FY2025 line items from Research360 (aggregator, based on filed consolidated statements); FY2024–FY2026 headline figures cross-checked against company filings.

Income statement (INR crore)

FY2026 total income: INR 312.96 crore per ScanX (company figure); Fyers reports INR 313.27 crore — minor discrepancy. FY2023 and FY2024 net profit incl. associate are aggregator figures (Zerodha) and could not be reconciled to primary filings.

Per-share data

Consolidated EPS computed as net profit incl. associate ÷ 256.78 million shares (no dilutive instruments disclosed). FY2026 standalone EPS of INR 4.85 is as filed.

Margins and growth

Revenue CAGR FY2021–FY2026: 26.7% (73.52 → 239.99). Revenue CAGR FY2023–FY2026: 23.7%.

Gross profit is not meaningful as reported: real-estate cost of construction (INR 60.02 crore standalone FY2026) and API material cost (INR 13.88 crore plus INR 2.55 crore inventory change) are both shown as expenses. Approximate standalone gross profit for FY2026 = 231.93 − 13.88 − 2.55 − 60.02 = INR 155.48 crore (67.0%), computed from the NSE FY2026 standalone filing.

Balance sheet (standalone, 31 March 2026, INR crore)

Source: NSE Integrated Filing (standalone, FY2026). Multi-year balance sheet history: consolidated net debt INR 10.08 crore at March 2025 (Zerodha, aggregator).

Cash flow (standalone FY2026, INR crore)

Observation: the standalone cash-flow statement presents dividend income as an operating-to-investing reclassification; OCF of INR 117.40 crore included a INR 47.15 crore release from inventories (real-estate deliveries).

Commentary — trends, inflections, drivers

Revenue inflection (FY2023–FY2025). Revenue nearly tripled between FY2022 (INR 78 crore) and FY2025 (INR 222 crore), driven almost entirely by real estate, which rose from INR 46 crore to INR 190 crore as Townhouse24, The Gardens and earlier Alembic City phases were delivered and recognised. FY2026 growth slowed to 8.2% as real estate plateaued (+2.0%) — consistent with a gap between the completion of earlier phases and the handover of Park Crescent (due July 2027) and The Villas (due August 2028). Q1 FY2027 revenue of INR 48.74 crore (−2.0% YoY) confirms the lull.

Margin peak and normalisation. EBITDA margin (excluding other income) expanded from 15% in FY2021 to a peak of 42% in FY2025, as high-margin land-based real-estate revenue scaled against a largely fixed employee base. It eased to ~37% in FY2026 because the API mix rose (lower margin) and Q3 FY2026 absorbed a INR 1.44 crore Labour Code provision.

Earnings quality. Other income (chiefly APL dividends) has averaged INR 60–90 crore annually since FY2022 and routinely exceeds operating EBITDA. Consolidated net profit is dominated by associate income: in FY2026 APL contributed INR 191.45 crore of the INR 317.38 crore total (60%). Alembic Limited's earnings therefore track APL's earnings cycle more than its own operations.

Balance sheet. The company is effectively debt-free (gross debt INR 10.64 crore), with INR 89 crore of current investments. Capital deployment in FY2026 shifted toward investment property and PPE (INR 76.65 crore combined, versus OCF of INR 117.40 crore), signalling a build-out of the leasing portfolio.

OCI volatility. Standalone FY2026 OCI was −INR 94.65 crore, driven by a fair-value decline in equity instruments (items not reclassified to P&L −INR 103.63 crore pre-tax), most plausibly the Paushak stake whose carrying value fell from INR 416.02 crore to INR 162.52 crore over the RPT reporting period. The magnitude of the decline exceeds the full-year OCI charge, implying that part of the movement may reflect valuation timing or a partial disposal; the filing does not reconcile this, and it is flagged as not fully verified.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationship to Alembic LimitedRoleSource

Nirayu Private Limited

Holding company (promoter)

Principal promoter vehicle

FY2026 RPT disclosure

Alembic Limited

Listed parent of operating businesses

API, real estate, power, investments

—

Alembic City Limited

Wholly owned subsidiary

Real-estate/leasing related; recipient of corporate guarantee

FY2026 RPT disclosure

Alembic Pharmaceuticals Limited

Associate (~28.4–28.5%)

Formulations & API pharma major

FY2026 RPT; Zonebourse

Paushak Limited

Investee (~19.1%), promoter-group company; carried at fair value

Phosgene-based specialty chemicals

Zonebourse; FY2026 RPT

Shreno Limited / Shreno Engineering Limited

Promoter-group companies

Engineering, real estate undertaking (post-2019 scheme)

FY2026 RPT

Alembic CSR Foundation

Other related party

CSR execution

FY2026 RPT

Segment Overview

SegmentContentsProducts/services

Active Pharmaceutical Ingredients (API)

Bulk drug manufacturing

Fermentation- and chemistry-based APIs (molecule list not publicly disclosed in sources reviewed)

Real Estate

Development, leasing, consultancy

Residential projects (townhouses, villas, apartments), commercial leasing, project management & marketing consultancy

Segment revenue (INR Cr)

Segment revenue (INR Cr)FY2021FY2022FY2023FY2024FY2025FY2026

Real Estate

45.046.0101.0125.74189.67193.40

API

28.532.326.531.7532.2246.59

Total revenue from operations

73.5278.22127.24157.49221.89239.99

Revenue by Segment (%) and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Real Estate share of revenue (%)

58.879.479.885.580.6

API share of revenue (%)

41.320.820.214.519.4

Real Estate YoY growth (%)

2.2119.624.550.82.0

API YoY growth (%)

13.3-18.019.81.544.6

Revenue by Segment

Segment result (INR Cr)FY2024FY2025FY2026

Real Estate — consolidated

51.2688.06—

Real Estate — standalone

—83.9078.59

API — standalone

——5.65

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment margin (%)

Segment margin (%)FY2024FY2025FY2026

Real Estate margin, consolidated

40.846.4—

Real Estate margin, standalone

—46.142.4

API margin, standalone

——12.1

Segment Assets & Liabilities

Segment balance (INR Cr)Mar-2024Mar-2025Dec-2025Mar-2026 (standalone)Jun-2026

Real Estate segment assets

367.00443.13489.18501.65528.73

Real Estate segment liabilities

76.8299.4780.6071.9077.65

API segment assets

———180.81—

Total segment assets

——673.18682.46711.01

Revenue History

QuarterRevenueReal EstateAPI (derived)PBTNet profit incl. associate

Q1 FY2026 (Jun-25)

49.7536.8012.9519.7861.64

Q2 FY2026 (Sep-25)

55.8645.5610.3084.78128.49

Q3 FY2026 (Dec-25)

74.3460.8413.5025.7660.12

Q4 FY2026 (Mar-26)

60.0450.219.8318.4367.13

Q1 FY2027 (Jun-26)

48.7437.0311.7117.3464.89

Income Statement

Metric (INR Cr)FY2021FY2022FY2023FY2024FY2025FY2026

Revenue from operations

73.5278.22127.24157.49221.89239.99

Other income

10.2789.1864.2654.7774.8972.97

Total income

83.79167.40191.50212.26296.78312.96

Operating profit / EBITDA excl. other income

11.0713.9340.3356.8793.7189.37

Depreciation

3.944.866.727.8410.6312.01

Finance cost

0.360.390.471.112.471.57

Exceptional items

00-10.61000

Profit before tax

17.0497.8686.80102.69155.50148.76

Net profit before associate

————144.57125.93

Share of associate (APL) profit

————166.10191.45

Net profit incl. associate

——191269310.68317.38

Standalone net profit

13.3685.7179.2792.89141.95124.54

Per-share metric (INR)

Per-share metric (INR)FY2022FY2023FY2024FY2025FY2026

EPS consolidated, basic = diluted (computed)

—7.4410.4812.1012.36

EPS standalone, basic = diluted

3.343.093.625.534.85

Dividend per share

——2.402.402.40

Margin / growth (%)

Margin / growth (%)FY2021FY2022FY2023FY2024FY2025FY2026

EBITDA margin (excl. other income)

15.117.831.736.142.237.2

PBT margin on revenue

23.2125.168.265.270.162.0

PAT before associate / revenue

————65.252.5

Revenue growth YoY

—6.462.723.840.98.2

Cost line (standalone)

Cost line (standalone)FY2026% of revenue

Cost of materials consumed

13.886.0

Change in inventories

2.551.1

Employee benefit expense

37.4416.1

Cost of construction

60.0225.9

Other expenses

30.3513.1

Depreciation

12.015.2

Finance cost

1.570.7

Total expenses

157.8168.0

Other income

72.7731.4

PBT

146.8963.3

Tax (current 22.00 + deferred 0.35)

22.35—

PAT

124.5453.7

Balance Sheet Item Details

Balance sheet item31-Mar-2026

Property, plant & equipment

169.95

Capital work-in-progress

1.50

Investment property

299.59

Non-current investments (APL at cost, Paushak at FV, others)

259.85

Other non-current assets

40.00

Inventories (incl. real-estate WIP)

52.24

Current investments

89.05

Trade receivables

30.21

Cash & cash equivalents

1.10

Other bank balances

1.87

Total assets

957.70

Equity share capital

51.36

Other equity

770.10

Total equity

821.46

Long-term borrowings

6.61

Short-term borrowings

4.03

Total debt

10.64

Net debt (debt − cash − bank − current investments)

-81.38

Total current assets

186.85

Total current liabilities

96.31

Working capital

90.54

Goodwill & intangibles

0

Cash flow item

Cash flow itemFY2026

Profit before tax

146.89

Operating cash flow before tax

136.37

Income tax paid

18.97

Net cash from operating activities

117.40

Capex — PPE

38.25

Capex — investment property

38.41

Total capex

76.65

Free cash flow (OCF − capex)

40.75

Dividends received (investing)

62.95

Interest received

1.40

Net purchase of investments (16,981.54 − 13,029.30 lakh)

39.52

Net cash used in investing

-52.04

Dividends paid

61.41

Repayment of borrowings

3.81

Interest paid

1.57

Buybacks

0

Net cash used in financing

-66.79

Net change in cash

-1.43

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2026 standaloneFY2025 consolidated (aggregator)Comment

ROE (%)

15.213.28

Standalone on closing equity; Research360 consolidated

ROA (%)

13.012.41

Standalone on closing assets

ROCE (%)

—12.4

Screener (pre-FY2026)

Current ratio (x)

1.94—

186.85 / 96.31

Debt / equity (x)

0.013—

Effectively debt-free

Net debt / EBITDA (x)

-0.93—

Net cash position

Interest coverage (x)

94.6—

(PBT + interest) / interest

Asset turnover (x)

0.24—

Holdco asset base depresses turnover

Debtor days

47.541.7

FY2026 computed (30.21/231.93×365); Screener prior

Dividend payout (% of standalone PAT)

49.463.8

61.6/124.54; Screener 5-yr average

Region revenue (INR Cr)

Region revenue (INR Cr)FY2024FY2025FY2026

India (real estate, wholly domestic)

125.74189.67193.40

API (domestic + export, split not disclosed)

31.7532.2246.59

Segment Overview — Real Estate

SegmentIndiaExportComment

Real Estate

100% (Vadodara, Gujarat)

0%

All projects are in Vadodara

Share Price & Returns

HorizonReturn (%)As ofSource

6 months

10.42

Oct 2026 (ScanX live widget)

ScanX

1 year

-2.31

Oct 2026 (ScanX live widget)

ScanX

1 year

-7.87

14 Feb 2026

iocharts

Year-to-date 2026

-11.54

mid-2026 (price INR 89.51)

Zonebourse

Price point (INR)

Date

Source

—
112.12

~mid-2025

Finology

—
95.47

14 Feb 2026

iocharts

—
91.31

26 Feb 2026

Research360

—
86.87

11 Aug 2026

Univest

—
97.36

Oct 2026 (ScanX widget at time of research)

ScanX

—

52-week range

70.5 – 126 (Screener, 2026 snapshot)

Screener

—

Valuation Multiples

MultipleAlembic LtdBasis

P/E (consolidated, FY2026 EPS 12.36)

7.9x

At INR 97.36

P/E (standalone EPS 4.85)

20.1x

At INR 97.36

P/B (consolidated)

~1.0x

iocharts 0.97 (Feb 2026); Research360 BVPS ~INR 91

EV/EBITDA

~30.5x

iocharts, Feb 2026 (on operating EBITDA ex-associate)

EV/Sales

~10.4x

Market cap ~INR 2,500 crore less net cash ~INR 81 crore / revenue INR 240 crore

Dividend yield

~2.5%

INR 2.40 / INR 97.36

Components

ComponentValue (INR Cr)Basis

APL stake (56,097,544 × INR 829.65)

4,654

APL price 7 Aug 2026 (MoneyWorks4Me)

Paushak stake (carrying value)

163

FVOCI at 31 Mar 2026

Net cash & current investments (standalone)

81

31 Mar 2026

Real estate + API + power (book: investment property + PPE)

470

31 Mar 2026 book values

Indicative gross asset value

5,368

Sum

Market capitalisation

~2,500

INR 97.36

Implied discount to indicative GAV (%)

~53

Computed

Peer Comparison

CompanyMarket cap (INR Cr)P/E (x)DateSource

Alembic Ltd

~2,500

7.9 (consolidated)

Oct 2026

Computed

Ganesh Housing

6,17667.22026

Screener

Arvind SmartSpaces

Not captured

Not captured

——

Alembic Pharma (associate)

~14,952

22.52026

Screener

Dividend metric

Dividend metricFY2024FY2025FY2026

DPS (INR)

2.402.402.40

Dividend as % of face value

120120120

Capital Markets

ItemStatus

Buyback authorisations

None current; last buyback FY2019

Debt maturity

Gross debt INR 10.64 crore (LT INR 6.61 crore; ST INR 4.03 crore); no listed debt securities; not a high-value debt-listed entity

Analyst Conclusions

Guidance and expectations

Alembic Limited provides no guidance and has no published consensus. The most relevant forward indicators are: (a) APL's raised FY2027 outlook (mid-teens revenue growth; US generics mid-to-high teens; 15+ US launches) — positive for associate income, which should exceed FY2026's INR 191.45 crore if APL delivers; and (b) the real-estate delivery calendar, where the next large handovers (Park Crescent, 72 units) fall in FY2028, implying subdued real-estate revenue in FY2027 (Q1 FY2027 RE revenue was flat at INR 37.03 crore).

Bull case

  1. Look-through value re-rating: the APL stake alone (~INR 4,654 crore) is roughly 1.9x Alembic Limited's market cap; any catalyst (simplification, higher payout, value-unlocking) could compress the ~50% discount.

  2. APL earnings momentum: Q1 FY2027 APL PAT +12% and revenue +26%, with guidance raised, should lift associate income and consolidated EPS beyond INR 12.36.

  3. Cash-rich, debt-free operating base: INR 81 crore net cash plus INR 299.59 crore investment property supports dividends, rental growth and new project launches without dilution.

Bear case

  1. Structural holdco discount: 70.88% promoter control, sparse disclosure and absence of a value-unlocking mandate may keep the discount permanent.

  2. Operating stagnation: pre-associate PAT fell 12.9% in FY2026 and ~12% in Q1 FY2027; real-estate revenue has plateaued at ~INR 190 crore with small project sizes.

  3. Investment value erosion: the Paushak stake's carrying value declined sharply in FY2026 (OCI −INR 94.65 crore), and APL itself is exposed to US generic pricing risk.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Q2 FY2027 results (Alembic Ltd and APL)Oct–Nov 2026APL dividend timing; RE handovers; API trajectory
APL US launches and USFDA inspection outcomesOngoing FY2027Associate income
Park Crescent construction progress (RERA quarterly updates)QuarterlyFY2028 revenue visibility
New RERA registrations in Alembic CityAny timePipeline replenishment
Board refresh (independent director vacancy)FY2027Governance quality
Disclosure improvements under new MDFY2027 AGM/annual reportCould narrow discount
Paushak share price / any stake transactionsOngoingOCI and capital allocation
FY2027 dividend decisionMay 2027Payout sustainability

Analyst verdict

Alembic Limited is a textbook Indian promoter holding company: a 119-year-old corporate shell whose economic value now resides overwhelmingly in a minority stake in a far larger listed pharmaceutical business. Its own operations — a land-based Vadodara real-estate franchise and a sub-scale API unit — are profitable and conservatively financed, but they are small, lumpy and opaquely disclosed. FY2026 illustrated the pattern precisely: revenue grew a modest 8.2% to INR 240 crore, the company's own net profit fell 13%, and yet consolidated earnings edged up 2% to INR 317 crore entirely because the associate APL earned more.

The valuation arithmetic is the investment case. At roughly INR 97 per share, the market capitalisation of about INR 2,500 crore is around half the market value of the APL stake alone, before attributing anything to the real-estate assets (INR 470 crore at book), the Paushak stake or net cash. On consolidated earnings the stock trades below 8x — cheap by any absolute measure — and offers a ~2.5% dividend yield that is effectively pre-funded by APL's dividend.

The difficulty is that discounts of this kind in Indian family holdcos are durable rather than temporary. Nothing in the filings signals a value-unlocking agenda: there is no buyback, no stated payout policy beyond a flat INR 2.40, no investor communication, and real-estate growth is constrained by small, slow project phases. The leadership transition to Udit Amin is the one genuine wildcard; better disclosure or capital-allocation changes could shift sentiment.

For investors needing a catalyst, the operating business is too small and the governance structure too closed to expect rapid convergence toward look-through value. Monitor APL's FY2027 delivery and any signal of strategic change from the new MD.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleCategoryBorn / ageBoard tenureBackgroundSource

Chirayu R. Amin

Chairman

Non-Executive, Non-Independent (Promoter)

4 Dec 1946 / 79

Director since 20 Aug 1967

MBA (USA); with company since 1983; Executive Chairman of APL; director of Paushak, Shreno, Nirayu; past President of FICCI and ICC India; past VP of BCCI

NSE governance filing Apr 2026; company website

Udit C. Amin

Managing Director

Executive (Promoter family)

14 May 1980 / 46

Director since 24 Apr 2013; MD w.e.f. 1 Oct 2025 (also MD from Mar 2016)

Economics (international trade), University of Michigan; previously Director & President – Operations; director of Paushak, Shreno, Nirayu

NSE governance filing; website; AR 2015-16

Malika C. Amin

Non-Executive Director (MD & CEO until 31 Dec 2025)

Non-Executive, Non-Independent

22 Oct 1954 / 71

Since 2 Jul 1988

MA; whole-time director of Shreno; director of Suvid Hospitals

NSE governance filing; website

Jain Parkash

Non-Executive Director

Non-Executive, Non-Independent

——

Ex-Punjab Chemicals & Crop Protection and Tagros Chemicals; whole-time director of Paushak

Website; Muthoot Securities

Rati Desai

Independent Director

Independent

——

Also director of Alembic City Ltd (per website note)

Muthoot Securities; website

Girish Hirode

Independent Director

Independent

———

Muthoot Securities

Geeta Goradia

Independent Director

Independent

———

Muthoot Securities

Mayur Jadeja

Independent Director

Independent

———

Muthoot Securities

Sanjeev Shah

Independent Director

Independent

———

Muthoot Securities

Sameer Khera

Independent Director

Independent

——

Manufacturing management (SPJIMR); MD of SEE Linkages

Website

Mayank Amin

Independent Director (deceased)

Independent

—

Appointed ~2023

Website carries an intimation of his demise (date not captured)

Website; AR 2023 notice

Keval Thakkar

Company Secretary & Compliance Officer

KMP

—2,026—

Board intimation May 2026

CFO

—

KMP

——

Not identified in sources reviewed

—

“—” = not publicly disclosed.

Executive Leadership Team

ExecutiveStock

Udit Amin (MD)

Nil (no ESOP disclosed)

Governance Overview

Governance attributeStatus

Chair / CEO separation

Formally separate (Non-Executive Chairman; MD), but both roles held by father and son

Committees

Audit, Nomination & Remuneration, Stakeholders' Relationship, CSR (statutory); Udit Amin is a committee member since 6 May 2014 (committee name per filing)

Related-party intensity

High: material transactions with APL (sales INR 28.02 crore H2 FY2026; omnibus approval up to INR 80.26 crore), Alembic City Ltd (INR 21.36 crore), Paushak, Shreno, Nirayu (royalty INR 0.16 crore paid to Nirayu)

RPT policy

Updated 7 Feb 2025; published on website

Audit opinion

Unmodified, FY2026 (CNK & Associates LLP)

Board & Management Changes

DateChangeContext

1 Oct 2025

Udit Amin designated Managing Director

Generational transition within the promoter family

1 Jan 2026

Malika Amin relinquishes MD & CEO; continues as Non-Executive Director

Completes handover to Udit Amin

2025–2026

Demise of Independent Director Mayank Amin

—
2026

Keval Thakkar signs as Company Secretary

Earlier CS: Drigesh Mittal

Major Shareholders

Shareholder classStake (%)DateSource

Promoter & promoter group

70.88

Dec 2024 (unchanged through 2025 per INDmoney "promoter holding unchanged")

Finology; Zerodha

— of which Nirayu Private Limited

≥41.11 (2018; increased via creeping acquisitions)

Mar 2018

Annual Return 2017-18

— of which Shreno Limited

13.69

Mar 2019

Annual Return 2018-19

Promoter pledge

0.00

Dec 2024

Finology

Public & institutions

29.12

Dec 2024

Derived

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning

Real estate (Gujarat)

Arvind SmartSpaces (Ahmedabad, Lalbhai Group)

Multi-city, JV/development-partnership model; HDFC Capital platform

Real estate (Gujarat)

Ganesh Housing Corporation (Ahmedabad)

Land-rich, very high-margin; residential, commercial, IT parks

Real estate (Vadodara)

Local Vadodara developers (unlisted)

Direct competition for premium buyers; share data not available

Real estate (Gujarat)

Goyal & Co., Shivalik Group (unlisted)

Ahmedabad-centred premium developers

API

Aarti Drugs

Large-volume domestic API maker

API

Solara Active Pharma Sciences

Pure-play API exporter

API

Granules India

Large-volume paracetamol/metformin API

API (fermentation)

Concord Biotech

Fermentation-based APIs (immunosuppressants)

Holding-company peers

Bombay Burmah Trading, Kama Holdings, Tata Investment Corporation, Bajaj Holdings, Maharashtra Scooters

Listed holdcos trading at discounts to look-through value

Peer Comparison FY2026

MetricAlembic LtdArvind SmartSpacesGanesh HousingAlembic Pharma (associate, context)

Revenue from operations

239.99564.05511.37

Q1 FY2027: 2,149.77

Revenue growth YoY (%)

8.2-20.9-46.7

Q1 FY2027: 25.7

Operating profit

89.37172.33449.70

Q1 FY2027 EBITDA pre-R&D: 523

Operating margin (%)

37.230.687.9

24 (pre-R&D)

Net profit

317.38103.38316.26

Q1 FY2027: 173.07

R&D intensity (%)

—

Not applicable

Not applicable

Not captured

“—” = not publicly disclosed.

Company Snapshot

$27.7M

Revenue

256

Employees

1907

Founded

Vadodara, India

Headquarters

SWOT Analysis

Strengths

  • Debt-free balance sheet: gross debt INR 10.64 crore against equity of INR 821.46 crore (standalone, 31 Mar 2026); interest coverage ~95x.
  • High-margin real estate: consolidated real-estate segment margin of 46.4% in FY2025 and 42.0% in 9M FY2026 (filings).
  • Valuable listed stake: 56.1 million APL shares worth ~INR 4,654 crore at INR 829.65 (7 Aug 2026), ~1.9x Alembic Limited's own market capitalisation.
  • Dividend self-funding: APL dividends of INR 62.95 crore covered the INR 61.41 crore dividend paid in FY2026 (standalone cash flow).
  • Consistent payout: DPS of INR 2.40 maintained for FY2025 and FY2026 (FY2026 note 2); 5-year average payout ~64% (Screener).
  • Revenue scale-up: revenue CAGR of 26.7% over FY2021–FY2026 (73.52 → 239.99).

Weaknesses

  • Earnings dependence on associate: 60% of FY2026 consolidated net profit came from APL (INR 191.45 / 317.38 crore).
  • Declining operating profit: pre-associate net profit fell 12.9% in FY2026 (INR 144.57 → 125.93 crore) and Q1 FY2027 PAT fell ~11.9% YoY.
  • Low disclosure: no investor presentation, bookings, land-bank or project pipeline data published.
  • Sub-scale API: INR 46.59 crore revenue with a Q4 FY2026 segment loss of INR 1.17 crore (standalone).
  • Related-party concentration: RPT sales to APL and Alembic City Ltd of ~INR 49 crore in H2 FY2026 alone.
  • Shrinking headcount: employees fell from 285 (FY2025) to ~256 (FY2026), possibly signalling contraction in API operations (cause not disclosed).

Opportunities

  • Holdco discount narrowing: market cap (~INR 2,500 crore) is roughly half the look-through value of the APL stake alone.
  • APL growth acceleration: APL raised FY2027 growth guidance to mid-teens after 26% Q1 revenue growth (Aug 2026), lifting associate income.
  • Pipeline deliveries: Park Crescent (72 units, possession July 2027) and The Villas (completion Aug 2028) underpin FY2028–FY2029 real-estate revenue.
  • Rental annuity: investment property of INR 299.59 crore with INR 38.41 crore of FY2026 additions can deepen recurring income.
  • API outsourcing tailwinds: API revenue grew 44.6% in FY2026; China+1 and APL's own 33% API growth may sustain offtake.
  • Generational leadership: Udit Amin's elevation (Oct 2025) could bring strategic refresh, including better disclosure.

Threats

  • Real-estate cyclicality: listed Gujarat peers saw FY2026 revenue declines of 21–47%.
  • Paushak value erosion: Paushak carrying value fell sharply during FY2026; standalone OCI −INR 94.65 crore.
  • US generics risk at APL: pricing pressure and USFDA compliance risks flow through to associate income.
  • Regulatory cost creep: Labour Code provision (INR 1.44 crore) and RERA compliance obligations.
  • Key-person/promoter concentration: Chairman is 79; promoter group holds 70.88%, limiting minority influence.
  • Liquidity/valuation: small free float (~29%) and retail-dominated register can perpetuate the holdco discount.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
4 Apr 2025NSE seeks clarification from Alembic Ltd on unusual volume movementMarket surveillance; no material information disclosed
Apr 2025RTA (now MUFG Intime) updates contact detailsAdministrative
May 2025FY2025 audited results: revenue INR 221.89 crore (+40.9%); net profit incl. associate INR 310.68 crore; DPS INR 2.40Record year
Aug 2025Q1 FY2026 results: revenue INR 49.75 crore; net profit incl. associate INR 61.64 croreSteady start
Aug 2025Investee Paushak approves 1:2 split and 3:1 bonusStake now 4.70 million shares
1 Oct 2025Udit Amin designated Managing DirectorLeadership transition
Nov 2025Q2 FY2026 results: PBT INR 84.78 crore (dividend income); net profit incl. associate INR 128.49 croreSeasonal dividend spike
21 Nov 2025New Labour Codes effective; INR 1.44 crore provision booked in Q3Cost headwind
18 Dec 2025Associate APL receives USFDA final approval for Travoprost ophthalmic solutionLook-through positive
1 Jan 2026Malika Amin steps down as MD & CEO; continues as Non-Executive DirectorGovernance change
12 Jan 2026APL receives USFDA tentative approval for Bosutinib tabletsLook-through pipeline
27 Jan 2026APL receives USFDA final approval for Difluprednate ophthalmic emulsionLook-through positive
6 Feb 2026APL receives USFDA approval for a Parkinson's disease therapy; plans 4–5 US launches in Q4Look-through positive
12 Feb 2026Q3 FY2026 results: record quarterly revenue INR 74.34 crore; RE INR 60.84 croreReal-estate handovers
7 Apr 2026Regulation 74(5) compliance certificate for Q4 FY2026Routine
16 Apr 2026Corporate governance filing confirms board changesDisclosure
22 Apr 2026Second 100-day "Saksham Niveshak" campaign for unclaimed dividendsInvestor servicing
23–26 Apr 2026APL incorporates German subsidiary; Fingolimod approval (US$145 M market); demise of APL director Saibal MukherjeeAssociate developments
8 May 2026Board meeting intimation; trading window closed from 1 Apr 2026Routine
15 May 2026APL FY2026 results; Q4 consolidated net profit INR 214.54 crore on revenue INR 1,847.72 croreDrives associate income
19 May 2026FY2026 results: revenue INR 239.99 crore (+8.2%); net profit incl. associate INR 317.38 crore (+2.2%); standalone PAT down to INR 124.54 crore; DPS INR 2.40Flat headline; associate-led
20 May 2026Reminder to claim unpaid dividends by 31 Aug 2026 before IEPF transferRoutine
Jun 2026KYC/dematerialisation reminder to physical shareholdersRoutine
4 Aug 2026APL Q1 FY2027: revenue +26% to INR 2,150 crore; PAT +12% to INR 173 crore; guidance raised to mid-teens growthStrong positive for Alembic Ltd's associate income
11 Aug 2026Q1 FY2027 results: revenue INR 48.74 crore (−2.0%); PBT INR 17.34 crore; PAT pre-associate ~INR 15 crore (−11.9%); net profit incl. associate INR 64.89 crore (+5.3%)Operating softness offset by APL
Jan–Apr 2026RERA progress: Park Crescent 36% → 45%; The Villas 56%Delivery pipeline intact

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 735.2 Mn in FY2021 to INR 2,399.9 Mn in FY2026.
Alembic Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2021FY2022FY2023FY2024FY2025FY2026
Revenue from operations735.2782.21,272.41,574.92,218.92,399.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Alembic Limited — Audited Financial Results, quarter & year ended 31 March 2025 (alembiclimited.com)
  2. Alembic Limited — Unaudited Financial Results, 30 June 2025 (alembiclimited.com)
  3. Alembic Limited — Unaudited Financial Results, quarter & half-year ended 30 September 2025 (alembiclimited.com)
  4. NSE Integrated Filing (Q3 FY2026, consolidated), 12 Feb 2026 (nsearchives.nseindia.com)
  5. NSE Integrated Filing (FY2026, standalone, incl. balance sheet, cash flow, RPT), 19 May 2026 (nsearchives.nseindia.com)
  6. NSE Integrated Filing (Q1 FY2027, consolidated), 11 Aug 2026 (nsearchives.nseindia.com)
  7. NSE Integrated Filing (Governance), 16 Apr 2026 (nsearchives.nseindia.com)
  8. ScanX — Alembic FY26 results summary (scanx.trade)
  9. Alembic Limited website (board, businesses) · alembiclimited.com
  10. Alembic Limited Annual Reports 2015-16 and 2016-17; Extracts of Annual Return 2017-18 and 2018-19 (alembiclimited.com)
  11. Kotak Securities — Alembic Ltd company background (kotakneo.com)
  12. Research360 — Alembic Ltd financials (research360.in)
  13. Screener — Alembic Ltd (screener.in)
  14. Zonebourse — Alembic Limited company profile (zonebourse.com)
  15. Morningstar — ALEMBICLTD profile (morningstar.com.au)
  16. Finology Ticker — Alembic (ticker.finology.in)
  17. Zerodha Markets — Alembic (zerodha.com)
  18. Fyers — Alembic P&L (fyers.in)
  19. iocharts — ALEMBICLTD.NSE (preview.iocharts.io)
  20. Univest — Alembic Q1 FY27 results (univest.in)
  21. INDmoney — Alembic Ltd (indmoney.com)
  22. Muthoot Securities — Alembic board list (muthootsecurities.com)
  23. Aurum PropTech RERA records: The Villas Phase 1, The Gardens, Park Crescent (aurumproptech.in)
  24. Gharpe listings: Alembic Townhouse24, The Villas, Park Crescent (gharpe.com)
  25. Alembic Pharmaceuticals Q1 FY27 press release (alembicpharmaceuticals.com)
  26. PTI via HDFC Sky — Alembic Pharma Q1 FY27 (hdfcsky.com)
  27. Multibagg — Alembic Pharma Q1 FY27 guidance (multibagg.ai)
  28. MoneyWorks4Me — Alembic Pharma share price (7 Aug 2026) (moneyworks4me.com)
  29. Screener — Alembic Pharmaceuticals (screener.in)
  30. Paushak profiles: Screener ( IIFL (: screener.in · indiainfoline.com
  31. Arvind SmartSpaces FY2026 · stockanalysis.com
  32. Ganesh Housing FY2026 · screener.in
  33. Simply Wall St — Alembic Ltd and Alembic Pharmaceuticals management (simplywall.st)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.